Chinese investors wager $105M on an IPO-bound biotech looking to push RNAi as mainstream cancer therapy
Shortly after Sirnaomics brought in a $47 million Series C for its small interfering RNA pipeline last year, Patrick Lu — the founder, president and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.